GlassScriptPhysician profile
Christine A White
NPI 1336124114
$1,722.91
in general payments reported to CMS, 2019-2025
19 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $16.96 · 2021: $33.38 · 2022: $278 · 2023: $389 · 2024: $376 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.11 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $542.46 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $263.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $215.46 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $102.32 | 2021-2023 | Invega Sustenna |
| Alkermes, INC. | $81.03 | 2022-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $75.30 | 2023-2025 | Austedo, Austedo Xr, Austedo Xr |
| Merck Sharp & Dohme LLC | $72.90 | 2019-2024 | Vaxelis, Gardasil, Gardasil 9 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.39 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $50.97 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $47.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $38.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.86 | 2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $35.51 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $19.67 | 2025 | Vowst |
| Pfizer INC. | $17.88 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.79 | 2025 | Mounjaro, Zepbound |
| Abbvie INC. | $17.01 | 2024 | |
| Corcept Therapeutics | $14.71 | 2024 | Korlym |
| Baxter Healthcare | $14.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.